Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment

Nummular eczema (NE) is a distinctive eczematous dermatitis characterized by an eruption of coin-shaped erythematous, edematous, vesicular, and crusted patches that tend to expand as papulovesicular satellite lesions appear at the periphery and fuse with the main plaque. This pruritic disorder classically affects the extensor aspect of the extremities, trunk, and buttocks. Patients generally report poor quality of life, demanding early and effective treatment. Although topical therapy is the mainstay of management, treatment escalation may be required in severe cases. Dupilumab, a human monoclonal antibody that targets both IL-4 and IL-13, has shown efficacy for moderate to severe atopic dermatitis and other immune-mediated disorders. Here, we report a six-year-old boy with severe and extremely pruritic NE unresponsive to topical and classic systemic treatments, showing complete and maintained remission of all skin signs and symptoms under dupilumab treatment.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-03-23
DOI
https://doi.org/10.7759/cureus.81038
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment

Ricardo Romiti, Ana Flavia Moraes, Julia‐Tatjana Maul, Luisa R Romiti
1 links
Cureus
Dermatology and Skin Diseases
article

Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment

Ricardo Romiti, Ana Flavia Moraes, Julia‐Tatjana Maul, Luisa R Romiti
article en

Abstract

Nummular eczema (NE) is a distinctive eczematous dermatitis characterized by an eruption of coin-shaped erythematous, edematous, vesicular, and crusted patches that tend to expand as papulovesicular satellite lesions appear at the periphery and fuse with the main plaque. This pruritic disorder classically affects the extensor aspect of the extremities, trunk, and buttocks. Patients generally report poor quality of life, demanding early and effective treatment. Although topical therapy is the mainstay of management, treatment escalation may be required in severe cases. Dupilumab, a human monoclonal antibody that targets both IL-4 and IL-13, has shown efficacy for moderate to severe atopic dermatitis and other immune-mediated disorders. Here, we report a six-year-old boy with severe and extremely pruritic NE unresponsive to topical and classic systemic treatments, showing complete and maintained remission of all skin signs and symptoms under dupilumab treatment.

CureusVol. 17(3)
Universidade de São Paulo (BR), Universidade de Caxias do Sul (BR), University Hospital of Zurich (CH), Universidade de Santo Amaro (BR), Universidade São Francisco (BR)
Zero hunger
Openalex Percentile: Top 88%
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment — Ricardo Romiti, Ana Flavia Moraes, et al. · Cureus (2025) | TGRS Research Map | TGRS